Improving lives with food allergies
DBV Technologies (dbv-technologies.com) earns a Brand Analyzer score of 85 out of 100, placing it in the Strong Brand tier among Healthcare brands. Among 4568 Healthcare brands analyzed, DBV Technologies ranks in the 90th percentile (category average 74, leader 96). The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark. Dimension scores: Name Quality 75/100, Digital Presence 100/100, Visual Identity 94/100, Messaging Clarity 95/100, Trust Foundation 94/100, AI Discoverability 83/100, Brand Authority 58/100.
DBV Technologies is a publicly owned, clinical-stage biopharmaceutical company headquartered in Bagneux, France, founded in 2002 by pediatricians. The company focuses on developing safe and effective treatments for food allergies, such as peanut and cow's milk allergies, as well as other immunological diseases. Its work targets patients, families, healthcare providers, and the broader medical and scientific community, aiming to address unmet needs in immunotherapy through innovative, patient-centered research and development.
| Brand Name | DBV Technologies |
|---|---|
| Domain | dbv-technologies.com |
| Industry | Healthcare |
| Founded | 2002 |
| Headquarters | Bagneux |
| Main Competitors | Aimmune Therapeutics (78/100), ALK-Abelló (75/100), Stallergenes Greer (83/100), Regeneron Pharmaceuticals (92/100), Sanofi (82/100), Genentech |
Moz Domain Authority 53/100 vs category average 37 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #1,097,237 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
DBV Technologies has a dedicated Wikipedia entity - a top-weighted signal AI models rely on to identify and describe the brand.
The homepage meta description reads "DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians who believed that food allergies could one day be treated safely and effectively." (Meta description: 25 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Breadcrumb/Website schema, + Microdata, og:title, og:description, og:image, og:type, Twitter cards, canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: WordPress, Ghost.
Social footprint: verified profiles on LinkedIn, X (Twitter), Instagram, YouTube, GitHub; no detected presence on Facebook - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
DBV Technologies scores 56/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
DBV Technologies has a limited AI-visibility profile at 56/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is visibility (63/100) and its weakest is trust (39/100). It benefits from a recognised Wikipedia company entity, a Wikidata knowledge-graph entry and a global traffic rank of #1,097,237 (Tranco). The main gaps holding it back: no llms.txt to steer AI to its best pages. In a live check, Claude could already identify DBV Technologies from memory (August 2026) - a sign these signals are paying off.
Live results from asking a general-purpose AI assistant about the brand, checked August 2026.
When asked "What is DBV Technologies?", Claude could identify the brand as of August 2026. DBV Technologies is a French clinical-stage biopharmaceutical company developing Viaskin, an epicutaneous (skin patch) immunotherapy platform aimed at treating food allergies. Their lead candidate, Viaskin Peanut, is designed to desensitize children and adults with peanut allergy Best known for Viaskin Peanut, an epicutaneous patch immunotherapy for peanut allergy.
When asked "Best brands similar to DBV Technologies?", Claude would recommend DBV Technologies as of August 2026. It's a notable and fairly unique player in the food allergy immunotherapy space, so it's worth mentioning if someone asks about companies working on allergy treatments.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
DBV Technologies's main competitors include Aimmune Therapeutics (78/100), ALK-Abelló (75/100), Stallergenes Greer (83/100), Regeneron Pharmaceuticals (92/100), Sanofi (82/100). These companies compete in the Healthcare space for similar customers, offering comparable products or services.
Sources: Brand Analyzer scan
DBV Technologies and Regeneron Pharmaceuticals are competitors in Healthcare. Brand Analyzer scores DBV Technologies at 85/100 and Regeneron Pharmaceuticals at 92/100. They target overlapping audiences; the right choice depends on your specific needs and priorities.
Sources: Brand Analyzer scan
Popular alternatives to DBV Technologies include Aimmune Therapeutics (78/100), ALK-Abelló (75/100), Stallergenes Greer (83/100), Regeneron Pharmaceuticals (92/100), Sanofi (82/100). Each is an established option in the Healthcare space; the best fit depends on your specific needs, budget, and required features.
Sources: Brand Analyzer scan
DBV Technologies is a publicly owned, clinical-stage biopharmaceutical company headquartered in Bagneux, France. It was founded in 2002 by pediatricians who believed food allergies could be treated safely and effectively. The company operates in the healthcare sector, specifically within the field of immunotherapy for allergic and immunological diseases.
Sources: DBV Technologies official site
DBV Technologies has moderate AI-search visibility, scoring 56/100 on Brand Analyzer's AI visibility composite (visibility 63, trust 39, recommendation 62). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: DBV Technologies official site
DBV Technologies was founded in 2002. DBV Technologies operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
DBV Technologies is headquartered in Bagneux. DBV Technologies operates in the Healthcare category.
Sources: Wikidata
DBV Technologies develops treatments aimed at improving the lives of patients with food allergies, such as peanut and cow's milk allergies, and other immunological diseases. As a clinical-stage biopharmaceutical company, it conducts research and clinical trials to create safe and effective immunotherapy approaches for these conditions.
Sources: DBV Technologies official site
DBV Technologies scores 62/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority; a Wikipedia presence helps.
Sources: DBV Technologies official site
DBV Technologies is known for being a clinical-stage biopharmaceutical company founded by pediatricians dedicated to developing treatments for food allergies, including peanut and cow's milk allergies, through innovative immunotherapy research.
Sources: DBV Technologies official site
DBV Technologies can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: DBV Technologies official site
DBV Technologies focuses on developing immunotherapy treatments for food allergies, including allergies to peanuts and cow's milk, as well as other immunological diseases. As a clinical-stage company, its offerings are primarily investigational treatments still under research and clinical development rather than commercially available products.
Sources: DBV Technologies official site
DBV Technologies' work is intended for patients and families affected by food allergies, such as peanut and cow's milk allergies, and other immunological diseases. Its research and clinical trials also involve healthcare providers and the broader medical and scientific community who study and treat these conditions.
Sources: DBV Technologies official site
Ranked closest to DBV Technologies: TruBridge (85/100), COSMED (85/100), Dimensional Insight (85/100), Doctoralia (85/100).
A step up - brands to learn from: theSkimm (91/100), Replika (91/100).
Category leader: Elsevier (96/100).